KBC Securities - UCB S.A. (UCB) UCB FIRST LOOK: FY23 conference call feedback

Report

KBC Securities

Thomas Vranken

UCB FIRST LOOK: FY23 conference call feedback

We share our main takeaways from the conference call hosted by UCB to discuss its FY23 results and 2024/2025 outlook.

29/02/2024 1 EN

Underlying

UCB S.A.

UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.

See profile

BE0003739530 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Thomas Vranken

Other Reports on these Companies

KBC Securities

Dynamic Top Pick List Update February 2026: Removing ASMi; Adding UCB

After today's changes (ASMi out, UCB in), we maintain a balanced approach in our Dynamic Top Pick List, with a particular emphasis on value stocks that have been overlooked. Our defensive holdings are overweight, including real estate, which stands to benefit from lower interest rates. We remove ASMi from our Dynamic Top Pick List as the recent share price performance has driven the valuation meaningfully ahead of fundamentals. Since early December, FY27 diluted EPS expectations have risen by approximately 9%, while the share price has rallied by around 40% over the same period, resulting in ...

February 5, 2026 February 5, 2026 1 EN

ING Financial Markets

Benelux Morning Notes

Flow Traders: Preview 4Q25 / Kinepolis: January reassures with US box office revenue up 14% YoY, France visitors up 15% YoY / Lotus Bakeries: Peer Mondelez 4Q25 results / MICC: Peer Mondelez 4Q25 results / RELX / Wolters Kluwer: Anthropic moves into Legal / Signify: Analyst lunch highlights / TomTom: 4Q25 results, bridging a gap / UCB: Evenity sales exceeded US$2.1bn in FY25 as per Amgen

February 4, 2026 February 4, 2026 1 EN

KBC Securities

Morning Notes : AKZA NA, ELI BB, MELE BB, UCB BB, ONWD BB

: AKZA NA, ELI BB, MELE BB, UCB BB, ONWD BB

February 4, 2026 February 4, 2026 1 EN

Aedifica Feedback analyst call

Feedback analyst call

20h 20h 1 EN

Guy Sips ... (+5)

Guy Sips
Hilde Van Boxstael
Lynn Hautekeete
Thomas Couvreur
Wim Lewi

Morning Notes : AED BB, OPTI BB, HOMI BB, KIN BB, MONT BB

: AED BB, OPTI BB, HOMI BB, KIN BB, MONT BB

23h / 16m 23h / 16m 1 EN

Wim Lewi

Wim Lewi

Montea Good things come to those who wait (for the big boxes)

Yesterday, Montea reported results that had an initial negative market reaction. After the call, the management and chairman Dirk De Pauw were available for a sit-down lunch to give more colour. The Q&A session centered on the pace of the development pipeline. Montea removed its project table as it believes it hurts their negotiating capacity. Now, it just reports an expected GLA of 236k sqm that will be completed over the next 2 years. The reason why it takes longer to develop the landbank is also due to the selectivity of Montea to certain projects. It reserves its best plots for single tena...

23h / 43m 23h / 43m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

UCB FIRST LOOK: FY23 conference call feedback

We are a financial services provider for several types of professional clients, each with distinct needs.

Dynamic Top Pick List Update February 2026: Removing ASMi; Adding UCB

Benelux Morning Notes

Morning Notes : AKZA NA, ELI BB, MELE BB, UCB BB, ONWD BB

Aedifica Feedback analyst call

Morning Notes : AED BB, OPTI BB, HOMI BB, KIN BB, MONT BB

Montea Good things come to those who wait (for the big boxes)

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe